NMX1 for Oncology
Our lead program, NMX1, is a novel, patented, orally available small molecule with excellent safety and PK properties that inhibits mTOR, secretion of IL-11, and expression of CXCR4. This unique mechanism allows NMX1 to act on both the tumor and the tumor microenvironment to prevent cancer cell proliferation, invasion, and migration. In addition, NMX1 activates AMPK, protecting the heart to prevent cardiotoxicity, inflammation, and fibrosis. NMX1 is poised to have significant potential in Triple Negative Breast Cancer (TNBC) treatment by maintaining or enhancing the superior efficacy of anthracycline therapy while mitigating its long-term cardiotoxicity.
In addition to the initial indications, the Company is evaluating NMX1 in rare pediatric cancers such rhabdomyosarcoma, osteosarcoma, and neuroblastoma. Currently, NovoMedix is advancing NMX1 into IND-enabling studies.